Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2000

View Archived Issues

Corixa's leishmaniasis vaccine program receives additional funding

Neurocrine Biosciences reports results of phase II trial with NBI-5788 in MS

Serotonergic receptor ligands under study at Cerebrus for obesity and other disorders

New LHRH antagonists in the Abbott pipeline

New compounds from Japanese lab inhibit Th2-type cytokine production

Forbes Medi-Tech initiates phase II trial for CardioRex

Patent claim allowance for LCG-MAb received by Cytoclonal

Updated results from G-3139 clinical trial demonstrate durable response and survival

Health Canada approves Rituxan for treatment of NHL

Fuji Chemical prepares new peptides for the treatment of pain

AstraZeneca develops new class of MMP inhibitors with selectivity for MMP-13, MMP-9

Aminoalcohol-based beta3-agonists claimed by Fujisawa for incontinence, pollakiuria

Recent patent covers Merck's new tyrosine kinase inhibitors

Biological effects of SU-9516, a cdk inhibitor, studied in human colon cancer cells

Novel tumor-targeting approach taken by McGill scientists using chimeric molecules

Full human genome is sequenced for the first time

NewBiotics completes private placement and prepares to advance study of lead product

Nonsecosteroidal, nonhypercalcemic VDR agonist with antitumor activity designed at Ligand

Positive preclinical data obtained for naked DNA prostate cancer vaccine

NitroMed searches for new, more effective treatments for MED: nitrated PGE1 analogues

More stable antimalarial aminoquinolines sought by Tulane investigators

Teva completes acquisition of Novopharm

Fujisawa's COX-2 inhibitor FK-3311 protects against I/R injury in lung transplantation

Alexion to commence phase Ib pilot study of 5G1.1 in pemphigoid patients

Catechin consumption protects against atherosclerosis in mouse model

Synthetic factor Xa inhibitor better than LMWH in rat model of DIC

Boston Life Sciences initiates phase II testing of Altropane in ADHD diagnosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...